Академический Документы
Профессиональный Документы
Культура Документы
Marieke Krol
iBMG/iMTA, Erasmus University Rotterdam
Active in teaching
Coordinater of the HTA course in two Master programs (Health Economics, health Economics, Policy and Law Coordinator of the HTA specialisation
HTA provides insight in costs and effects of (new) interventions compared with existing interventions What are the additional costs? What are the additional benefits? Are the benefits worth the extra expenses?
Cost-effectiveness ratio of B versus A What are the additional costs? What are the additional benefits?
ICER = Incremental cost-effectiveness ratio
(costs New - costs Old) (effects New effects Old) Common outcome: costs per QALY Are the benefits worth the extra expenses?
What is a QALY worth?
Perspective
Health care perspective
Include costs paid from the health care budget
Societal perspective
Include all relevant costs (and effects) E.g. out of pocket payments and productivity costs
Productivity costs
Costs associated with production loss and replacement costs due to illness, disability and death of productive persons, both paid and unpaid.
(Brouwer et al. Health Econ 1997: 6(5))
I.e. People suffering from ill health are commonly less productive, which involves costs.
Questions
Should work play a role in the decision to reimburse drug X?
What do you think as a stakeholder?
What are the barriers to inclusion of work in HTA in your national setting? Who are the stakeholders in your country? Where and how to start the debate in your country?